Lakewood Amedex Biotherapeutics Inc

Lakewood-Amedex Biotherapeutics filed an 8-K on June 17, 2026 announcing a 1-for-10 reverse stock split effective at 4:01 p.m. ET on June 19, 2026, with shares trading on a split-adjusted basis when Nasdaq opens on June 22, 2026. The company also disclosed that the reverse split coincides with a proportional reduction of authorized shares and a new CUSIP number (51255A201).

StockTitan summarizes a filing in which Lakewood-Amedex Biotherapeutics reported Q1 results and disclosed subsequent events, including a private sale of Series C convertible preferred stock closing April 21, 2026 for gross proceeds of about $7.5 million (net about $6.8 million). The same disclosure ties these subsequent events to the company’s April 23, 2026 Nasdaq listing and related conversions.

StockTitan reports the SEC declared Lakewood-Amedex Biotherapeutics’ S-1 effective on May 13, 2026 (4:00 P.M.), with the StockTitan entry dated May 14, 2026. The EFFECT filing relates to the company’s Nasdaq registration/going-public process rather than an unrelated prior history item.

OTC Markets shows a 424B4 prospectus received on May 14, 2026 for the resale of shares issuable upon conversion of the company’s Series C preferred, plus additional advisor-related shares issued in April 2026. This is IPO-adjacent registration activity tied to the newly public listing rather than general background reporting.